While anti-CD73 therapy boosts the efficacy of anti-PD-L1 and anti-CTLA4 ICB in murine tumour models54, it is not clear whether additional targeting of CD39 would offer any additional benefit in NSCLC.33 This evidence concerns the gene ENTPD1 and neoplasm.